For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
MiRNA371-Guided MAnagement in Testicular germ cell tumors- MAGMA GCT
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Interim results from the CCTG PR.22 (DASL-HiCaP ANZUP 1801) clinical trial, has seen a delay in the spread of prostate cancer. The findings were presented by Dr. Tamim Niazi at the Presidential Symposium at European Society for Medical Oncology (ESMO) 2026 Congress. “Early results indicate that intensifying standard radiation and hormone therapy with Darolutamide may decrease the risk of metastatic spread in prostate cancer patients at higher risk of disease recurrence or progression,” says Dr. Tamim Niazi, the DASL-HiCaP study co-chair and Radiation Oncologist at Jewish General Hospital. “If supported by longer-term data, this approach offers a meaningful opportunity to extend the time patients live without cancer progression.”
The CCTG PAC5 trial is now open to patient enrollment in Canada. The trial is evaluating whether lanreotide can reduce the risk of postoperative pancreatic fistula (POPF), one of the most important complications following pancreatic surgery.
The Canadian Cancer Society recently announced a $525,000 Challenge Grant award for a CO.21 implementation study. The Challenge Grants program supports cancer research projects that are focused on solving a cancer related problem.
CCTG, EORTC and UK3CR welcome the G7 Leaders’ announcement recognizing cancer as a global priority.
Now opened in Canada for patients with PTCL, investigating whether an intensive treatment approach can reduce the risk of the disease returning after initial chemotherapy.
Final results from the CCTG HN.9 (EORTC 1740-HNCG) were presented at ASCO 2026, highlighting the challenges of reducing treatment intensity while maintaining outcomes for oropharyngeal cancer patients .
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER+/HER2-neg Breast Cancer with Recurrence Score ≤ 25 (RxFINE-Low)
Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy
Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
Adjuvant tebentafusp (IMCgp100) vs obs in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma (ATOM Trial)
NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
June marks both National Indigenous History Month and Pride Month. It is a time to learn about and honour the diverse cultures, histories, and experiences of First Nations, Inuit, and Métis Peoples, and to celebrate the strength, resilience, and contributions of 2SLGBTQI+ communities. It is also an opportunity to reflect on our shared responsibility to advance equitable, inclusive, and culturally safe clinical trial design and conduct.
CCTG would like to welcome Melanie Keats as the new patient representative supporting the Gynecologic Disease Site Committee. Melanie resides in Halifax Nova Scotia and is a a Professor and Associate Research Scholar, Health Populations Research Institute at Dalhousie University as well as a Nova Scotia Health Authority Affiliated Scientist and Co-Director Physical Activity and Cancer (PAC) Lab.
One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.
MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence.
